一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 7 月 4 日 （二） 股东大会召开的地点：北京市大兴区中关村科技园区大兴生物医药产业 基地庆丰西路 55 号公司三层会议室 证券代码：688068 证券简称：热景生物 公告编号：2025-049 北京热景生物技术股份有限公司 2025年第三次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 216 | | --- | --- | | 普通股股东人数 | 216 | | 2、出席会议的股东所持有的表决权数量 | 56,565,640 | | 普通股股东所持有表决权数量 | 56,565,640 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 65.7951 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（% ...

证券代码：688068 证券简称：热景生物 公告编号：2025-050 北京热景生物技术股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 北京热景生物技术股份有限公司（以下简称"公司"）第四届董事会第一次 会议于 2025 年 7 月 4 日以现场和通讯相结合的方式在公司三层会议室召开。全 体董事一致同意豁免本次董事会会议的提前通知期限，与会的各位董事已悉知与 所议事项相关的必要信息。本次会议由董事长林长青先生主持，会议应到董事 7 人，实到董事 7 人。本次会议的召集和召开符合《中华人民共和国公司法》《上 海证券交易所科创板股票上市规则》等相关法律法规、规范性文件及《北京热景 生物技术股份有限公司章程》的有关规定。 二、董事会会议审议情况 1、审议通过《关于选举公司第四届董事会董事长的议案》 经审议，同意选举林长青先生为公司第四届董事会董事长。 表决结果：同意 7 票、反对 0 票、弃权 0 票。 第四届董事会第一次会议决议公告 2、审议通过《关于选举公司第四届董事会专门委员会委员及召 ...

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.: 010-50867666 传真/Fax: 010-56916450 网址/Website: www.kangdalawyers.com 法律意见书 康达股会字【2025】第 0309 号 二〇二五年七月 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 法律意见书 北京市康达律师事务所 关于北京热景生物技术股份有限公司 2025 年第三次临时股东大会的法律意见书 北京市康达律师事务所 关于北京热景生物技术股份有限公司 2025 年第三次临时股东大会的 康达股会字【2025】第0309号 致：北京热景生物技术股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券 法》（以下简称"《证券法》"）、《上 ...

Core Viewpoint - The company Hotgen Biotech (688068.SH) has announced that its main business involves the research, production, and sales of in vitro diagnostic reagents and related instruments, while its biopharmaceutical innovation and early cancer screening businesses are independently operated by joint ventures [1] Group 1 - The main business of Hotgen Biotech is focused on in vitro diagnostic reagents and related instruments [1] - The biopharmaceutical innovation and early cancer screening businesses are managed by joint ventures including ShunJing Pharmaceutical, YaoJing Genetics, ZhiYuan Biotech, and AoRui Biotech [1] - The related businesses are characterized by high research and development investment and significant research risks [1]

Core Viewpoint - The in vitro diagnostics sector experienced a slight increase of 0.24% on July 4, with a net outflow of funds amounting to 42.33 million [1] Group 1: Market Performance - A total of 18 stocks in the sector saw gains, while 49 stocks declined [1] - The top decliners included Dongfang Ocean (-6.51%), Xilong Scientific (-3.81%), and Nearshore Protein (-2.54%) [1][1] Group 2: Stock Performance - Notable gainers included: - Hotgen Biotech with a price of 194.81 and an increase of 20.08%, attracting a net fund inflow of 2.125 million [1] - Saily Medical at 21.08, up 10.02%, with a net inflow of 1.758 million [1] - Zhongyuan Union at 25.87, rising 9.99%, with a net inflow of 1.38 billion [1] - Decliners included: - Botao Biotech at 37.34, down 3.38%, with a net outflow of 1.087 million [1] - Maike Biotech at 7.99, down 2.44%, with a net inflow of 176.92 thousand [1]

Group 1 - The average stock price of the Sci-Tech Innovation Board is 30.66 yuan, with 38 stocks priced over 100 yuan, and the highest priced stock is Cambricon at 547.47 yuan [1][2] - Among the stocks priced over 100 yuan, 126 stocks increased in price today, while 456 stocks decreased, with an average increase of 0.47% for the hundred-yuan stocks [1][2] - The average premium of the hundred-yuan stocks relative to their issue price is 342.63%, with the highest premiums from Baili Tianheng, Anji Technology, and Hotgen Biotech at 1143.52%, 1134.82%, and 938.74% respectively [1][2] Group 2 - The net outflow of main funds from the hundred-yuan stocks today totaled 3.56 billion yuan, with the highest net inflows from Hotgen Biotech, Zhongwei Company, and Chip Source at 7962.57 million yuan, 6166.17 million yuan, and 4054.76 million yuan respectively [2] - The total margin balance for the hundred-yuan stocks is 262.17 billion yuan, with the highest margin balances held by Cambricon, Haiguang Information, and Zhongwei Company at 43.37 billion yuan, 36.53 billion yuan, and 27.35 billion yuan respectively [2] - The hundred-yuan stocks are concentrated in the electronics, pharmaceutical biology, and computer industries, with 20, 8, and 5 stocks respectively [1][2]

Market Overview - A-shares showed strength in cyclical and growth sectors, with the Shanghai Composite Index reaching a high of 3497.22 points during the day, closing up 0.32% [1] - The total market turnover exceeded 1.45 trillion yuan, an increase of 121 billion yuan from the previous day [1] - For the week, the Shanghai Composite Index rose by 1.4%, while the Shenzhen Component Index fell by 0.25% and the ChiNext Index increased by 1.5% [1] Sector Performance - The financial sector, including banks and securities, saw significant gains, with several bank stocks hitting new highs [3] - The innovation drug sector experienced a surge, with companies like Huazhang Bio and YamaTon achieving consecutive daily limit increases [5] - The gaming sector also showed strong performance, with stocks like Giant Network and Ice Age Network rising over 9% [9] Policy and Regulatory Environment - Recent announcements from the National Medical Products Administration (NMPA) indicate support for brain-computer interface medical devices, which is expected to boost related sectors [7] - The National Healthcare Security Administration's new regulations include innovative drugs in the insurance directory, further enhancing market sentiment [3][7] Innovation Drug Sector - The innovation drug sector saw significant gains, with companies like Huazhang Bio achieving a cumulative stock price increase of over 650% in the past year [5] - The NMPA's new measures aim to support high-end medical device innovation, which could benefit leading companies in the sector [7] Gaming Sector - The gaming sector is experiencing a positive trend, with a record number of game approvals in June, indicating a healthy consumption environment [11] - The first Shanghai International Animation Month event is set to enhance the gaming and animation culture, potentially driving further growth in the sector [12]

Group 1 - The Alzheimer's concept sector rose by 1.80%, leading the gains among concept sectors, with 18 stocks increasing in value [1][2] - Notable gainers included Hotgen Biotech with a 20% limit up, and other companies like Jingxin Pharmaceutical and Haizheng Pharmaceutical also reached their limit up [1][2] - The sector saw a net inflow of 372 million yuan from main funds, with 17 stocks receiving net inflows, and six stocks exceeding 30 million yuan in net inflow [2][3] Group 2 - The top three stocks by net inflow were Haizheng Pharmaceutical (105 million yuan), Jingxin Pharmaceutical (88.79 million yuan), and Hotgen Biotech (79.62 million yuan) [2][3] - The net inflow ratios for leading stocks were 9.03% for Haizheng Pharmaceutical, 7.51% for Jingxin Pharmaceutical, and 8.09% for Hotgen Biotech [3][4] - Stocks with significant declines included Fujilai, Wohua Pharmaceutical, and Wanbangde, with declines of 1.61%, 1.30%, and 1.29% respectively [1][5]

Group 1 - The recombinant protein concept sector increased by 0.80%, ranking 7th among concept sectors, with 16 stocks rising, including Hotgen Biotech and Zhongyuan Union, both hitting the daily limit [1][2] - The leading gainers in the recombinant protein sector included Huayu Pharmaceutical and Shenzhou Cell, which rose by 18.79% and 16.46% respectively [1][2] - The sector experienced a net inflow of 0.35 billion yuan, with 13 stocks receiving net inflows, and 9 stocks exceeding 10 million yuan in net inflow [2][3] Group 2 - Zhongyuan Union led the net inflow with 1.83 billion yuan, followed by Huayu Pharmaceutical and Hotgen Biotech with net inflows of 1.19 billion yuan and 796.26 million yuan respectively [2][3] - The top stocks by net inflow ratio included Zhongyuan Union at 20.01%, Huayu Pharmaceutical at 12.48%, and Tonghua Dongbao at 9.43% [3][4] - The overall performance of the recombinant protein sector was supported by significant capital inflows, indicating strong investor interest [2][3]

智通财经7月4日电，创新药概念反复走强，热景生物涨超15%，续创历史新高，此前塞力医疗4连板， 中源协和涨停，神州细胞、广生堂、上海谊众、荣昌生物等涨幅靠前。消息面上，国家医保局近日印发 《2025年基本医保目录及商保创新药目录调整申报操作指南》，首次将商业健康保险创新药目录纳入调 整方案。 创新药概念反复走强 热景生物涨超15%创历史新高 ...